No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
HPB : the official journal of the International Hepato Pancreato Biliary Association（2023）
摘要
CA19-9 response to NAC may serve as the marker for effective NAC. These findings warrant validation in a multi-institutional study.
更多查看译文
关键词
resectable pancreatic cancer,effective neoadjuvant chemotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要